# Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

> **NCT04941365** · NA · WITHDRAWN · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle**

## Conditions studied

- Metastatic Melanoma
- Metastatic Breast Cancer
- Advanced Renal Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Non-small Cell Lung Cancer Stage III
- Healthy

## Interventions

- **DIAGNOSTIC_TEST:** single arm

## Key facts

- **NCT ID:** NCT04941365
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-07
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** please refer to NCT05621837
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941365, "Quantifying Systemic Immunosuppression to Personalize Cancer Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04941365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*